4.7 Article

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Editorial Material Oncology

CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert

Yuwen Zhu et al.

CLINICAL CANCER RESEARCH (2014)

Article Oncology

Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

Kunle Odunsi et al.

CANCER IMMUNOLOGY RESEARCH (2014)

Article Oncology

Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR

Joannes F. M. Jacobs et al.

INTERNATIONAL JOURNAL OF CANCER (2007)

Review Cell Biology

Directions in the immune targeting of cancer: Lessons learned from the cancer-testis AgNY-ESO-1

Theo Nicholaou et al.

IMMUNOLOGY AND CELL BIOLOGY (2006)

Article Oncology

Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma

M Wölfl et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)

Article Multidisciplinary Sciences

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

ID Davis et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)

Article Multidisciplinary Sciences

Immunomic analysis of human sarcoma

SY Lee et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)